Last updated: April 26, 2026
Teva Pharmaceuticals International GmbH v. Apotex Inc. | 1:17-cv-01164: Litigation Status, Patent-Tradecraft, and Business Impact
What is the case and where does it sit procedurally?
Case: Teva Pharmaceuticals International GmbH v. Apotex Inc.
Docket: 1:17-cv-01164
Parties: Teva Pharmaceuticals International GmbH (plaintiff) v. Apotex Inc. (defendant)
Note on procedural completeness: No qualifying public docket record, asserted patent list, claim construction, trial posture, injunction activity, or final disposition is provided in the prompt. Without that record, a complete and accurate litigation summary (including the specific patents at issue, rulings, and outcome) cannot be produced.
Because the required elements for a litigation summary and analysis (asserted patent numbers, key court orders, and end-state disposition) are not available in the provided materials, a complete and accurate response cannot be generated.
What patents were asserted and what was claimed?
The prompt does not include:
- The asserted patent(s) and their publication/application numbers
- The drug product and label/NDC(s) implicated
- The asserted claims or infringement theories
- The invalidity/unenforceability contentions raised by Apotex
- Any claim construction outcomes
Without the asserted patent portfolio and claim-level record, litigation analysis cannot be completed.
What did the court decide (motions, claim construction, summary judgment, and outcome)?
The prompt does not provide any of the following:
- Dismissal/transfer outcomes
- Claim construction orders
- Summary judgment decisions on infringement and validity
- Posture at the time of filing (ANDA-related timing, 30/180-day exclusivity events, or settlement triggers)
- Final judgment, consent judgment, or dismissal terms
- Injunction issuance or denial
Without the orders and decision text, a reliable litigation analysis cannot be produced.
What is the business impact for Teva and Apotex?
To assess impact, the following record items are required:
- Whether Teva obtained an injunction or prevailed in final judgment
- Whether Apotex launched “at risk,” entered a stipulated launch date, or was blocked by injunction
- Any damages or royalty structure tied to the end date of infringement
- Whether the litigation ended in settlement with explicit patent carve-outs or timed entry
No settlement terms or commercial outcome are included in the prompt.
Key Takeaways
- The request requires a patent-accurate litigation summary and analysis for Teva Pharmaceuticals International GmbH v. Apotex Inc., 1:17-cv-01164.
- The prompt does not include the case record needed to produce a complete and accurate summary (asserted patents, key orders, claim construction, and disposition).
- A litigation-grade response cannot be generated from the provided information.
FAQs
-
What is the docket number for the case?
1:17-cv-01164
-
Who are the parties?
Teva Pharmaceuticals International GmbH and Apotex Inc.
-
Which court heard the matter?
Not provided.
-
Which patents were asserted?
Not provided.
-
What was the final outcome?
Not provided.
References (APA)
[1] No citable case documents or authoritative sources were provided in the prompt.
